--- title: "Amarin Corporation (AMRN) news: settlement" url: "https://aibio.space/companies/amarin/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "AMRN settlement news: Amarin settles Hikma patent and antitrust cases over generic Vascepa. Amarin Corporation plc (NASDAQ: AMRN), Ireland." --- AMRN Amarin Corporation plc NASDAQ · Ireland # Amarin Corporation (AMRN) news AMRN settlement news Legal · 2026-10-28 ## [Amarin settles Hikma patent and antitrust cases over generic Vascepa](https://aibio.space/news/amarin-settles-hikma-patent-antitrust-cases-generic-vascepa/) The 10-Q says the patent claims and Hikma's antitrust claims are to be dismissed with prejudice under settlements agreed on Oct 13. It also lists antitrust complaints from Dr. Reddy's, Teva and Apotex in New Jersey. ## Latest Amarin Corporation news 1. 2025-06-24 Distress [Amarin licenses VAZKEPA in Europe to Recordati for $25 million upfront and starts restructuring](https://aibio.space/news/amarin-licenses-vazkepa-europe-recordati-25-million-upfront-plans/) Amarin will receive $25 million upfront and up to $150 million in milestones under a 59-country license. It also expects a global restructuring to cut operating costs by approximately $70 million annually. 2. 2025-06-24 Distress [Amarin licenses Vazkepa in Europe to Recordati for $25 million upfront, plans restructuring](https://aibio.space/news/amarin-licenses-vazkepa-europe-recordati-25-million-upfront-plans/) Amarin is licensing Vazkepa in Europe to Recordati for a $25 million upfront payment and starting a restructuring that targets about $70 million in cost savings over the next 12 months, while the release gives no loss or cash-flow figures. 3. 2025-04-29 Listings [Amarin regains compliance with Nasdaq minimum bid price requirement](https://aibio.space/news/amarin-regains-compliance-nasdaq-minimum-bid-price-requirement/) Nasdaq confirmed on April 29, 2025 that the stock averaged at least $1.00 over 10 consecutive business days. Amarin will stay listed on Nasdaq. 4. 2025-04-09 Listings [Amarin sets 1-for-20 ADS ratio change for April 11 to keep Nasdaq listing](https://aibio.space/news/amarin-sets-1-20-ads-ratio-change-april-11-keep-nasdaq-listing/) Each American Depositary Share will represent twenty ordinary shares instead of one. The company says the aim is to meet Nasdaq's $1.00 minimum bid price. ## Amarin Corporation at a glance - **Ticker**: AMRN - **Listing**: NASDAQ - **Country**: Ireland - **Cash, Sep 30, 2026**: $323.4 million ### Related companies - [Cosmo](https://aibio.space/companies/cosmo-n-v/) SIX: CMHC - [Alkermes](https://aibio.space/companies/alkermes/) NASDAQ: ALKS - [Jazz Pharmaceuticals](https://aibio.space/companies/jazz-pharmaceuticals/) NASDAQ: JAZZ - [GH Research](https://aibio.space/companies/gh-research/) NASDAQ: GHRS - [Prothena Corporation](https://aibio.space/companies/prothena/) NASDAQ: PRTA - [Malin Corporation](https://aibio.space/companies/malin/) EURONEXT: MLC ### Also on NASDAQ - [Sanara MedTech](https://aibio.space/companies/sanara-medtech/) SMTI - [Kiniksa Pharmaceuticals International](https://aibio.space/companies/kiniksa-pharmaceuticals-international/) KNSA - [Enveric Biosciences](https://aibio.space/companies/enveric-biosciences/) ENVB - [Opus Genetics](https://aibio.space/companies/opus-genetics/) IRD - [EXOZYMES INC.](https://aibio.space/companies/exozymes/) EXOZ - [Achieve Life Sciences](https://aibio.space/companies/achieve-life-sciences/) ACHV ## Amarin Corporation annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$19.8 million](https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/) | [$20.9 million](https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/) | | Net income (loss) | [-$38.8 million](https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/) | [-$82.2 million](https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/) | | Cash from operations | [$6.7 million](https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/) | [-$31.0 million](https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/) | | Cash and equivalents | [$134.7 million](https://www.sec.gov/Archives/edgar/data/897448/000119312526435082/) | [$121.0 million](https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/) | | Short-term investments | [$167.9 million](https://www.sec.gov/Archives/edgar/data/897448/000119312526435082/) | [$173.2 million](https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/) | Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $156.5 million, plus short-term investments of $166.9 million, $323.4 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Amarin Corporation Has Amarin Corporation settled a lawsuit? Our latest story on this, dated Oct 28, 2026: "Amarin settles Hikma patent and antitrust cases over generic Vascepa". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/amarin-settles-hikma-patent-antitrust-cases-generic-vascepa/). What is the ticker symbol of Amarin Corporation? Amarin Corporation plc trades under the ticker AMRN on NASDAQ. Where is Amarin Corporation listed? Amarin Corporation plc is listed on NASDAQ. What is the SEC CIK of Amarin Corporation? The SEC Central Index Key (CIK) for Amarin Corporation plc is 897448. Its filings are on SEC EDGAR. How many shares does Amarin Corporation have outstanding? 380,694 shares as of 2013-02-20, per the cover page of its 10-K filed 2013-02-28. Which country or territory is Amarin Corporation listed under? Our directory records Amarin Corporation plc under Ireland. What does Amarin Corporation do? Our directory classifies Amarin Corporation plc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Amarin Corporation? The ISIN recorded for Amarin Corporation plc is US0231114044. Does aibio.space cover Amarin Corporation? aibio.space lists Amarin Corporation plc among 2,820 public biotech companies and publishes its news here as stories appear. Where is Amarin Corporation incorporated? SEC records list its state or country of incorporation as X0. Is Amarin Corporation profitable? Amarin Corporation plc reported a net loss of $38.8 million for the fiscal year ended Dec 31, 2025, and generated $6.7 million of cash from operations, per its annual report to the SEC. How much does Amarin Corporation spend on research and development? $19.8 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Amarin Corporation have? $323.4 million in cash and short-term investments at Sep 30, 2026, per its 10-Q. What is the latest Amarin Corporation (AMRN) stock news? Our latest story on Amarin Corporation, dated Oct 28, 2026: "Amarin settles Hikma patent and antitrust cases over generic Vascepa". The 10-Q says the patent claims and Hikma's antitrust claims are to be dismissed with prejudice under settlements agreed on Oct 13. It also lists antitrust complaints from Dr. Reddy's, Teva and Apotex in New Jersey. [Source](https://aibio.space/news/amarin-settles-hikma-patent-antitrust-cases-generic-vascepa/). Is Amarin Corporation in financial distress? Our latest distress story, dated Jun 24, 2025: "Amarin licenses VAZKEPA in Europe to Recordati for $25 million upfront and starts restructuring". Amarin will receive $25 million upfront and up to $150 million in milestones under a 59-country license. It also expects a global restructuring to cut operating costs by approximately $70 million annually. [Source](https://aibio.space/news/amarin-licenses-vazkepa-europe-recordati-25-million-upfront-plans/). ## Investor discussion: Amarin Corporation Members talk about Amarin Corporation (AMRN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Amarin Corporation, newest first. Each line links the filing it comes from. 1. 2026-04-29 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/897448/000119312526188940/amrn-20260331.htm) 2. 2026-03-02 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm) 3. 2025-06-24 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 1.01,2.05,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/897448/000095017025089218/amrn-ex99_1.htm) 4. 2025-04-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/897448/000095017025060165/amrn-ex99_1.htm) 5. 2025-04-09 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/897448/000095017025052307/amrn-ex99_1.htm) 6. 2025-03-12 Listings Reported a reverse stock split. SEC Form 8-K (Items 2.02,3.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/897448/000095017025037618/amrn-ex99_1.htm) 7. 2024-11-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/897448/000095017024130263/amrn-20241122.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:AMRN on TradingView](https://www.tradingview.com/symbols/NASDAQ-AMRN/). ## SEC filings and registration - **SEC name**: Amarin Corp Plc\Uk - **CIK**: 897448 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: AMRN (Nasdaq) - **State or country of incorporation**: X0 - **Fiscal year ends**: December 31 - **Filer category**: Accelerated filer - **Business address**: SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2 - **Phone**: 353 1 6699 020 - **Shares outstanding**: 380,694 as of 2013-02-20 (10-K filed 2013-02-28) - **Former names**: AMARIN CORP PLC\UK; AMARIN PHARMACEUTICALS PLC; ETHICAL HOLDINGS PLC ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/897448/000119312526323845/amrn-20260630.htm) filed 2026-07-29 - [8-K](https://www.sec.gov/Archives/edgar/data/897448/000119312526323841/amrn-20260729.htm) filed 2026-07-29 - [8-K](https://www.sec.gov/Archives/edgar/data/897448/000119312526224771/amrn-20260513.htm) filed 2026-05-15 - [10-Q](https://www.sec.gov/Archives/edgar/data/897448/000119312526188940/amrn-20260331.htm) filed 2026-04-29 - [8-K](https://www.sec.gov/Archives/edgar/data/897448/000119312526188935/amrn-20260429.htm) filed 2026-04-29 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/897448/000119312526151417/amrn-20260410.htm) filed 2026-04-10 - [8-K](https://www.sec.gov/Archives/edgar/data/897448/000119312526129334/amrn-20260325.htm) filed 2026-03-27 - [10-K](https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm) filed 2026-03-02 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000897448), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Amarin Corporation plc is a public biotech or pharmaceutical company listed on NASDAQ under the ticker AMRN, recorded under Ireland. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Amarin Corporation plc - **Ticker**: AMRN - **Listing**: NASDAQ - **Country or territory**: Ireland - **Business scope**: Pharmaceuticals: Major - **ISIN**: US0231114044 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-AMRN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/amarin/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Amarin Corporation (AMRN) news: settlement", 2026-10-31, https://aibio.space/companies/amarin/